VUAB PHARMA A S has a total of 21 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2005. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BETA CAT PHARMACEUTICALS INC, CANCER TARGETED TECH LLC and PLACON THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | Canada | 3 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | United States | 3 | |
#5 | Australia | 2 | |
#6 | Czechia | 2 | |
#7 | Brazil | 1 | |
#8 | China | 1 | |
#9 | Israel | 1 | |
#10 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Special acyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Kacer Petr | 15 |
#2 | Kysilka Vladimir | 13 |
#3 | Mengler Jan | 12 |
#4 | Cerveny Libor | 9 |
#5 | Havlovic Karel | 6 |
#6 | Kysilka Vladimír | 4 |
#7 | Kalisz Tomas | 4 |
#8 | Cervený Libor | 2 |
#9 | Mikoška Miloš | 2 |
#10 | Tserveny Libor | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021043402A1 | New platinum iv complexes with substantially increased antitumor efficacy | |
CZ2014916A3 | Soluble platinum (II) complex with pyridinecarboxamidine ligand and process for preparing thereof | |
EP3189064A1 | Platinum (iv) complex with increased antitumor efficacy | |
CZ2012513A3 | Method of removing platinum compounds and metabolites thereof from urine of patients treated by cytostatics and apparatus for making the same | |
EP2029615A1 | A process for the preparation of an oxaliplatin | |
EP1874290A1 | A process for the preparation of an oxaliplatin preparation |